Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib

PURPOSE: Most lung cancers with activating epidermal growth factor receptor (EGFR) mutations respond to gefitinib, however resistance to this tyrosine kinase inhibitor (TKI) invariably ensues. The T790M mutation occurs in 50% and MET amplification in 20% of TKI-resistant tumors. Other secondary muta...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Costa, Daniel B., Nguyen, Kim-Son H., Cho, Byoung C., Sequist, Lecia V., Jackman, David M., Riely, Gregory J., Yeap, Beow Y., Halmos, Balazs, Kim, Joo H., Janne, Pasi A., Huberman, Mark S., Pao, William, Tenen, Daniel G., Kobayashi, Susumu
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2596582/
https://ncbi.nlm.nih.gov/pubmed/18981003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-1455
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados